June 02, 2020

Samsung Bioepis inks commercialization agreement with Biogen

PUBLISHED : November 07, 2019 - 10:55

UPDATED : November 07, 2019 - 17:52

  • 본문폰트 작게
  • 본문폰트 크게
  • 페이스북
  • 트위터
  • sms

South Korean pharmaceutical firm Samsung Bioepis said Nov. 7 it has entered into a new commercialization agreement worth $370 million with US partner Biogen.

Under the partnership, Biogen will be responsible of marketing and sales of Samsung Bioepis’ two ophthalmology biosimilars -- SB11 and SB15 -- that are currently in development.

The agreement also gives Biogen the option to extend its existing 10-year commercialization agreement for three anti-TNF biosimilars in Europe by five years.

“By building on this collaboration, we are excited to potentially expand the opportunity for patients living with ophthalmological conditions, who do not have access to life-changing medicines,” Samsung Bioepis CEO Christopher Hansung Ko said in a press release.

Samsung Bioepis, established in 2012, currently has biosimilars approved and marketed across Europe and the US -- Benepali, Imraldi, Ontruzant and Flixabi.

By Ram Garikipati and newswires (

  • 페이스북
  • 트위터
  • sms
Herald Corporation|CEO : Kwon Chung Won
Publisher. Editor : Kwon Chung Won
Chief Privacy Officer & Juvenile Protection Manager : Yang Sung-jin
Title : The Investor|Date of registration : 2015.04.28
Company Registration No. 104-81-06004
Mail-Order Business Registration 2016 - Seoul Yongsan - 00590
Huam-ro 4-gil 10, Yongsan-gu, Seoul, Korea
T : +82-2-727-0114|Business info
Gov’t registration No. Seoul 아04099